ClinicalTrials.gg
CompletedNCT01047345Updated Nov 27, 2018Results posted

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

A Phase 3 interventional study of V503 and Placebo to V503 in Cervical Cancers, Vulvar Cancers and Vaginal Cancers, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 12 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
924
Allocation
Randomized
Ages
12 Years to 26 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.

Enrollment
10th of 14
924 · median 1,206
Started
2010
the only one that year
Phase 3
9 of 14
2 open now
Registered
2nd of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 2nd registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 12 Years to 26 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™. Participants will receive vaccination with 9vHPV vaccine or placebo on Day 1, Month 2, and Month 6 of the Base Study. Participants who receive placebo in the Base Study will be eligible to receive vaccination with 9vHPV vaccine on Day 1, Month 2, and Month 6 of the Extension Study.

03

Conditions studied

  • Cervical Cancers
  • Vulvar Cancers
  • Vaginal Cancers
  • Genital Warts

Keywords

  • Cervical cancer
  • Genital warts
  • Human papillomavirus vaccine
  • GARDASIL™
04

Who can participate

Ages eligible
12 Years to 26 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants Age 12 to 15 Years:

  • Participant is in good health
  • Parent/legal guardian and participant agree to provide study personnel with a primary telephone number for follow-up
  • Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1
  • Participant has not received any other HPV vaccine
  • Participant is not yet sexually active

Participants Age 16 to 26 Years:

  • Participant is in good health
  • Participant agrees to provide a primary telephone number for follow-up
  • Participant received a 3-dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1
  • Participant has not received any other HPV vaccine
  • Participant has never had Papanicolaou (Pap) testing or has only had normal results
  • Participant has a history of 0 to 4 lifetime sexual partners at enrollment

Exclusion criteria

Exclusion Criteria:

All participants:

  • Participant has a history of severe allergic reaction that required medical intervention
  • Participant has any disorder that would contraindicate intramuscular injections
  • Participant is pregnant
  • Participant is or has an condition
  • Participant has had a splenectomy
  • Participant has received any immune globulin product or blood-derived product
  • Participant has participated in a HPV vaccine clinical trial

Participants Age 16 to 26 Only:

  • Participant expects to donate eggs during the study
  • Participant has a history of abnormal cervical result
  • Participant has a history of HPV-related external genital lesions, external genital cancer, HPV-related vaginal lesions, or vaginal cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
924 participants (actual)

Study arms

  • Experimental
    9vHPV Vaccine

    Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.

    Biological: V503

  • Placebo comparator
    Placebo

    Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.

    Biological: V503 · Biological: Placebo to V503

Interventions

  • BiologicalV503

    V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension

  • BiologicalPlacebo to V503

    Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.

    Time frame: up to 5 days after any vaccination - Base Study

  2. Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study

    Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.

    Time frame: up to 5 days after any vaccination - Base Study

  3. Percentage of Participants Who Experience a Systemic AE - Base Study

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.

    Time frame: up to 14 days after any vaccination - Base Study

  4. Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study

    An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.

    Time frame: up to 14 days after any vaccination - Base Study

  5. Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study

    An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" is defined as a vaccine-related SAE.

    Time frame: Up to 7 months - Base Study

  6. Percentage of Participants Who Experience a Severe Injection-site AE - Base Study

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter \>2 inches (\>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.

    Time frame: up to 5 days after any vaccination - Base Study

Secondary outcomes

  1. Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study

    Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

    Time frame: 4 weeks post-vaccination 3 (Month 7; End of Base Study)

Other outcomes

  1. Percentage of Participants Who Experience an SAE- Extension Study

    An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.

    Time frame: up to Month 7 - Extension Study

07

Results

Posted Dec 22, 2014

Participant flow

Base Study
Participant flow — Base Study
Milestone9vHPV Vaccine - Base StudyPlacebo - Base Study9vHPV Vaccine - Extension Study
Started6183060
Vaccination 16153060
Vaccination 26043040
Vaccination 35973000
Completed5963000
Not completed2260
Withdrew: Adverse event300
Withdrew: Lost to follow-up410
Withdrew: Protocol violation310
Withdrew: Withdrawal by subject1240
Extension
Participant flow — Extension
Milestone9vHPV Vaccine - Base StudyPlacebo - Base Study9vHPV Vaccine - Extension Study
Started00102
Vaccination 400102
Vaccination 50099
Vaccination 60095
Completed0096
Not completed006
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up005

Outcome measures

PrimaryPercentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.

Time frame:
up to 5 days after any vaccination - Base Study
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study91.143.9
PrimaryPercentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study

Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.

Time frame:
up to 5 days after any vaccination - Base Study
Reported as:
Number · Percentage of Participants
Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study6.53.0
Statistical analysis
  • 9vHPV Vaccine - Base Study vs Placebo - Base Study · Miettinen & Nurminen · p = 0.026 · Difference in percentages: 3.5 · 95% CI 0.5 to 6.2
PrimaryPercentage of Participants Who Experience a Systemic AE - Base Study

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.

Time frame:
up to 14 days after any vaccination - Base Study
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience a Systemic AE - Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Percentage of Participants Who Experience a Systemic AE - Base Study59.755.7
Statistical analysis
  • 9vHPV Vaccine - Base Study vs Placebo - Base Study · Miettinen & Nurminen · Difference in percentages: 4.0 · 95% CI -2.8 to 10.8
PrimaryPercentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study

An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.

Time frame:
up to 14 days after any vaccination - Base Study
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study0.30.3
Statistical analysis
  • 9vHPV Vaccine - Base Study vs Placebo - Base Study · Miettinen & Nurminen · Difference in percentages: 0.0 · 95% CI -1.5 to 0.9
PrimaryPercentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study

An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" is defined as a vaccine-related SAE.

Time frame:
Up to 7 months - Base Study
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study0.20.3
Statistical analysis
  • 9vHPV Vaccine - Base Study vs Placebo - Base Study · Miettinen & Nurminen · Difference in percentages: -0.2 · 95% CI -1.7 to 0.6
PrimaryPercentage of Participants Who Experience a Severe Injection-site AE - Base Study

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter \>2 inches (\>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.

Time frame:
up to 5 days after any vaccination - Base Study
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience a Severe Injection-site AE - Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Percentage of Participants Who Experience a Severe Injection-site AE - Base Study11.21.0
Statistical analysis
  • 9vHPV Vaccine - Base Study vs Placebo - Base Study · Miettinen & Nurminen · Difference in percentages: 10.2 · 95% CI 7.5 to 13.1
SecondaryPercentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study

Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.

Time frame:
4 weeks post-vaccination 3 (Month 7; End of Base Study)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study
Percentage of Participants9vHPV Vaccine - Base StudyPlacebo - Base Study
Anti-HPV 6 (n=511; n=251)100.0 (99.3 to 100.0)100.0 (98.5 to 100.0)
Anti-HPV 11 (n=515; n=261)100.0 (99.3 to 100.0)99.6 (97.9 to 100.0)
Anti-HPV 16 (n=515; n=261)100.0 (99.3 to 100.0)100.0 (98.6 to 100.0)
Anti-HPV 18 (n=515; n=261)100.0 (99.3 to 100.0)85.4 (80.6 to 89.5)
Anti-HPV 31 (n=515; n=261)99.8 (98.9 to 100.0)23.8 (18.7 to 29.4)
Anti-HPV 33 (n=515; n=261)99.8 (98.9 to 100.0)8.0 (5.0 to 12.0)
Anti-HPV 45 (n=515; n=261)98.3 (96.7 to 99.2)3.4 (1.6 to 6.4)
Anti-HPV 52 (n=515; n=261)99.6 (98.6 to 100.0)3.8 (1.9 to 6.9)
Anti-HPV 58 (n=515; n=261)99.8 (98.9 to 100.0)9.2 (6.0 to 13.4)
Statistical analysis
  • 9vHPV Vaccine - Base Study · Clopper-Pearson · p = <0.001 (statistical criterion of acceptability required that the lower bound of the 95% confidence interval (CI) for the proportion of participants seroconverting be greater than 90%) · Seroconversion rate: 99.8 · 95% CI 98.9 to 100.0
  • 9vHPV Vaccine - Base Study · Clopper-Pearson · p = <0.001 (statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%) · Seroconversion rate: 99.8 · 95% CI 98.9 to 100.0
  • 9vHPV Vaccine - Base Study · Clopper-Pearson · p = <0.001 (statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%) · Seroconversion rate: 98.3 · 95% CI 96.7 to 99.2
  • 9vHPV Vaccine - Base Study · Clopper-Pearson · p = <0.001 (statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%) · Seroconversion rate: 99.6 · 95% CI 98.6 to 100.0
  • 9vHPV Vaccine - Base Study · Clopper-Pearson · p = <0.001 (statistical criterion of acceptability required that the lower bound of the 95% CI for the proportion of subjects seroconverting be greater than 90%) · Seroconversion rate: 99.8 · 95% CI 98.9 to 100.0
Other pre-specifiedPercentage of Participants Who Experience an SAE- Extension Study

An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.

Time frame:
up to Month 7 - Extension Study
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience an SAE- Extension Study
Percentage of Participants9vHPV Vaccine - Extension Study
Percentage of Participants Who Experience an SAE- Extension Study2.0

Adverse events

Collected over Up to 5 days after any vaccination (Non-serious injection site AEs); up to 15 days after any vaccination (Non-serious systemic AEs) and up to 7 months (Serious AEs) - Base Study and Extension Study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
9vHPV Vaccine - Base Study—3/608 (0.5%)566/608 (93.1%)
Placebo - Base Study—3/305 (1%)197/305 (64.6%)
9vHPV Vaccine - Extension Study—2/99 (2%)0/99 (0%)
Most frequent serious events
Most frequent serious events
Event9vHPV Vaccine - Base StudyPlacebo - Base Study9vHPV Vaccine - Extension Study
Abdominal painGastrointestinal disorders0/6080/3051/99
DiarrhoeaGastrointestinal disorders0/6080/3051/99
Lumbar vertebral fractureInjury, poisoning and procedural complications0/6081/3050/99
Thoracic vertebral fractureInjury, poisoning and procedural complications0/6081/3050/99
MigraineNervous system disorders0/6081/3050/99
Abortion inducedSurgical and medical procedures0/6081/3050/99
AppendicitisInfections and infestations1/6080/3050/99
TonsillitisInfections and infestations1/6080/3050/99
SyncopeNervous system disorders1/6080/3050/99
Most frequent other events
Most frequent other events
Event9vHPV Vaccine - Base StudyPlacebo - Base Study9vHPV Vaccine - Extension Study
Injection site painGeneral disorders549/608117/3050/99
Injection site swellingGeneral disorders298/60818/3050/99
Injection site erythemaGeneral disorders258/60826/3050/99
HeadacheNervous system disorders190/60881/3050/99
NauseaGastrointestinal disorders52/60812/3050/99
Injection site pruritusGeneral disorders48/6084/3050/99
NasopharyngitisInfections and infestations47/60819/3050/99
PyrexiaGeneral disorders42/60810/3050/99
Oropharyngeal painRespiratory, thoracic and mediastinal disorders40/60812/3050/99
DizzinessNervous system disorders31/6086/3050/99

Baseline characteristics

Age, Customized
Age, Customized(Participants)9vHPV Vaccine - Base StudyPlacebo - Base StudyTotal
12 to 15 years12260182
16 to 26 years496246742
Sex: Female, Male
Sex: Female, Male(Participants)9vHPV Vaccine - Base StudyPlacebo - Base StudyTotal
Female618306924
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015 Nov 27;33(48):6855-64. doi: 10.1016/j.vaccine.2015.08.059. Epub 2015 Sep 26. PubMed 26411885 ↗
  • Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2):e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15. PubMed 27422279 ↗
  • Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Hum Vaccin Immunother. 2018 Feb 1;14(2):396-403. doi: 10.1080/21645515.2017.1403700. Epub 2017 Dec 14. PubMed 29211620 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Jun 2011, 15 months.

Results were first posted in Dec 2014, 3 years 6 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 15 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2010
First posted
Jan 12, 2010
StartActual
Feb 24, 2010
Primary completionActual
Jun 10, 2011
CompletionActual
Nov 28, 2015
Results first posted
Dec 22, 2014
Last update
Nov 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01047345
Responsible party
Sponsor
First posted
Jan 12, 2010
Start date
Feb 24, 2010
Primary completion
Jun 10, 2011
Completion
Nov 28, 2015
Results posted
Dec 22, 2014
Last update
Nov 27, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion